Sobi publishes Q2 2023 report: Growth and pipeline expansion
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter 2023Second quarter 2023 · Total revenue increased 26 per cent, +16 per cent at constant exchange rates, (CER)i, to SEK 4,872 M (3,876) · Haematology revenue increased 18 per cent at CER to SEK 3,430 M (2,688). Driven by Doptelet® +74 per cent at CER and the launch of Aspaveli®/Empaveli® SEK 144 M · Immunology revenue increased 29 per cent at CER to SEK 1,179 M (847). Driven by Gamifant® +73 per cent at CER and Kineret® +12 per cent at CER · Adjusted EBITAi margin expanded by 1